84358 Federal Register / Vol. 85, No. 248 / Monday, December 28, 2020 / Notices 

DEPARTMENT OF HEALTH AND 

HUMAN SERVICES 

National Institutes of Health 

National Heart, Lung, and Blood 

Institute; Notice of Closed Meeting 

Pursuant to section 10(d) of the 

Federal Advisory Committee Act, as 

amended, notice is hereby given of the 

following meeting. 

The meeting will be closed to the 

public in accordance with the 

provisions set forth in sections 

552b(c)(4) and 552b(c)(6), Title 5 U.S.C., 

as amended. The contract proposals and 

the discussions could disclose 

confidential trade secrets or commercial 

property such as patentable material, 

and personal information concerning 

individuals associated with the contract 

proposals, the disclosure of which 

would constitute a clearly unwarranted 

invasion of personal privacy. 

Name of Committee: National Heart, Lung, 

and Blood Institute Special Emphasis Panel; 

Improving Oxygen Delivery. 

Date: January 22, 2021. 

Time: 12:00 p.m. to 5:00 p.m. 

Agenda: To review and evaluate contract 

proposals. 

Place: National Institutes of Health, 6705 

Rockledge Drive, Bethesda, MD 20817 

(Virtual Meeting). 

Contact Person: Giuseppe Pintucci, Ph.D., 

Scientific Review Officer, Office of Scientific 

Review/DERA, National Heart, Lung, and 

Blood Institute, National Institutes of Health, 

6705 Rockledge Drive, Room 205–H, 

Bethesda, MD 20892, (301) 827–7969, 

Pintuccig@nhlbi.nih.gov. 

(Catalogue of Federal Domestic Assistance 

Program Nos. 93.233, National Center for 

Sleep Disorders Research; 93.837, Heart and 

Vascular Diseases Research; 93.838, Lung 

Diseases Research; 93.839, Blood Diseases 

and Resources Research, National Institutes 

of Health, HHS) 

Dated: December 18, 2020. 

David W. Freeman, 

Program Analyst, Office of Federal Advisory 

Committee Policy. 

[FR Doc. 2020–28530 Filed 12–23–20; 8:45 am] 

BILLING CODE 4140–01–P 

DEPARTMENT OF HEALTH AND 

HUMAN SERVICES 

National Institutes of Health 

National Institute on Aging; Amended 

Notice of Meeting 

Notice is hereby given of a change in 

the meeting of the Basic Neuroscience of 

Aging Review Committee, January 19, 

2021, 11:00 a.m. to January 21, 2021, 

04:00 p.m., National Institute on Aging, 

Gateway Building, 7201 Wisconsin 

Avenue, Bethesda, MD 20892 which 

was published in the Federal Register 

on November 25, 2020, 85 FR 75345. 

The meeting notice is amended to 

change the date of the meeting from 

January 20–21 to January 19–21, 2021. 

The meeting is closed to the public. 

Dated: December 18, 2020. 

Miguelina Perez, 

Program Analyst, Office of Federal Advisory 

Committee Policy. 

[FR Doc. 2020–28525 Filed 12–23–20; 8:45 am] 

BILLING CODE 4140–01–P 

DEPARTMENT OF HEALTH AND 

HUMAN SERVICES 

National Institutes of Health 

National Center for Advancing 

Translational Sciences; Notice of 

Closed Meeting 

Pursuant to section 10(d) of the 

Federal Advisory Committee Act, as 

amended, notice is hereby given of the 

following meeting. 

The meeting will be closed to the 

public in accordance with the 

provisions set forth in sections 

552b(c)(4) and 552b(c)(6), Title 5 U.S.C., 

as amended. The cooperative agreement 

applications and the discussions could 

disclose confidential trade secrets or 

commercial property such as patentable 

material, and personal information 

concerning individuals associated with 

the cooperative agreement applications, 

the disclosure of which would 

constitute a clearly unwarranted 

invasion of personal privacy. 

Name of Committee: National Center for 

Advancing Translational Sciences Special 

Emphasis Panel CTSA Review. 

Date: January 29, 2021. 

Time: 11:00 a.m. to 4:00 p.m. 

Agenda: To review and evaluate 

cooperative agreement applications. 

Place: National Center for Advancing 

Translational Sciences; National Institutes of 

Health, 6701 Democracy Boulevard, Room 

1080, Bethesda, MD 20892 (Virtual Meeting). 

Contact Person: Victor Henriquez, Ph.D., 

Scientific Review Officer, Office of Scientific 

Director, National Center for Advancing 

Translational Sciences, National Institutes of 

Health, 6701 Democracy Boulevard, Room 

1080, Bethesda, MD 20892–4878, 301–435– 

0813, henriquv@mail.nih.gov. 

(Catalogue of Federal Domestic Assistance 

Program Nos. 93.859, Pharmacology, 

Physiology, and Biological Chemistry 

Research; 93.350, B—Cooperative 

Agreements; 93.859, Biomedical Research 

and Research Training, National Institutes of 

Health, HHS) 

Dated: December 18, 2020. 

David W. Freeman, 

Program Analyst, Office of Federal Advisory 

Committee Policy. 

[FR Doc. 2020–28529 Filed 12–23–20; 8:45 am] 

BILLING CODE 4140–01–P 

DEPARTMENT OF HEALTH AND 

HUMAN SERVICES 

National Institutes of Health 

National Institute of Diabetes and 

Digestive and Kidney Diseases; Notice 

of Meetings 

Pursuant to section 10(d) of the 

Federal Advisory Committee Act, as 

amended, notice is hereby given of 

meetings of the National Diabetes and 

Digestive and Kidney Diseases Advisory 

Council. 

The meeting will be open to the 

public as indicated below, with a short 

public comment period at the end. The 

open session will be videocast and can 

be accessed from the NIH Videocasting 

and Podcasting website (http://

videocast.nih.gov). 

The meetings will be closed to the 

public in accordance with the 

provisions set forth in sections 

552b(c)(4) and 552b(c)(6), Title 5 U.S.C., 

as amended. The grant applications and 

the discussions could disclose 

confidential trade secrets or commercial 

property such as patentable material, 

and personal information concerning 

individuals associated with the grant 

applications, the disclosure of which 

would constitute a clearly unwarranted 

invasion of personal privacy. 

Name of Committee: National Diabetes and 

Digestive and Kidney Diseases Advisory 

Council. 

Date: May 12–13, 2021. 

Open: May 12, 2021, 10:00 a.m. to 1:15 

p.m. 

Agenda: To present the Director’s Report 

and other scientific presentations. 

Place: National Institutes of Health, Two 

Democracy Plaza, 6707 Democracy 

Boulevard, Bethesda, MD 20892 (Virtual 

Meeting). 

Closed: May 13, 2021, 1:25 p.m. to 1:45 

p.m. 

Agenda: To review and evaluate grant 

applications. 

Place: National Institutes of Health, Two 

Democracy Plaza, 6707 Democracy 

Boulevard, Bethesda, MD 20892 (Virtual 

Meeting). 

Contact Person: Karl F. Malik, Ph.D., 

Director, Division of Extramural Activities, 

National Institutes of Diabetes and Digestive 

and Kidney Diseases, 6707 Democracy 

Boulevard, Room 7329, MSC 5452, Bethesda, 

MD 20892, (301) 594–4757 malikk@

niddk.nih.gov. 

Name of Committee: National Diabetes and 

Digestive and Kidney Diseases Advisory 


tkelley on DSKBCP9HB2PROD with NOTICES
Federal Register / Vol. 85, No. 248 / Monday, December 28, 2020 / Notices 84359 

Council; Diabetes, Endocrinology and 

Metabolic Diseases Subcommittee. 

Date: May 12–13, 2021. 

Open: May 13, 2021, 10:00 a.m. to 11:30 

a.m. 

Agenda: To review the Division’s scientific 

and planning activities. 

Place: National Institutes of Health, Two 

Democracy Plaza, 6707 Democracy 

Boulevard, Bethesda, MD 20892 (Virtual 

Meeting). 

Closed: May 13, 2021, 11:45 a.m. to 1:15 

p.m. 

Agenda: To review and evaluate grant 

applications. 

Place: National Institutes of Health, Two 

Democracy Plaza, 6707 Democracy 

Boulevard, Bethesda, MD 20892 (Virtual 

Meeting). 

Contact Person: Karl F. Malik, Ph.D., 

Director Division of Extramural Activities, 

National Institutes of Diabetes and Digestive 

and Kidney Diseases, 6707 Democracy 

Boulevard, Room 7329, MSC 5452, Bethesda, 

MD 20892 (301) 594–4757, malikk@

niddk.nih.gov. 

Name of Committee: National Diabetes and 

Digestive and Kidney Diseases Advisory 

Council; Digestive Diseases and Nutrition 

Subcommittee. 

Date: May 12–13, 2021. 

Open: May 13, 2021, 10:00 a.m. to 11:30 

a.m. 

Agenda: To review the Division’s scientific 

and planning activities. 

Place: National Institutes of Health, Two 

Democracy Plaza, 6707 Democracy 

Boulevard, Bethesda, MD 20892 (Virtual 

Meeting). 

Closed: May 13, 2021, 11:45 a.m. to 1:15 

p.m. 

Agenda: To review and evaluate grant 

applications. 

Place: National Institutes of Health, Two 

Democracy Plaza, 6707 Democracy 

Boulevard, Bethesda, MD 20892 (Virtual 

Meeting). 

Contact Person: Karl F. Malik, Ph.D., 

Director Division of Extramural Activities, 

National Institutes of Diabetes and Digestive 

and Kidney Diseases, 6707 Democracy 

Boulevard, Room 7329, MSC 5452 Bethesda, 

MD 20892, (301) 594–4757 malikk@

niddk.nih.gov. 

Name of Committee: National Diabetes and 

Digestive and Kidney Diseases Advisory 

Council; Kidney, Urologic and Hematologic 

Diseases Subcommittee. 

Date: May 12–13, 2021. 

Open: May 13, 2021, 10:00 a.m. to 11:30 

a.m. 

Agenda: To review the Division’s scientific 

and planning activities. 

Place: National Institutes of Health, Two 

Democracy Plaza, 6707 Democracy 

Boulevard, Bethesda, MD 20892 (Virtual 

Meeting). 

Closed: May 13, 2021, 11:45 a.m. to 1:15 

p.m. 

Agenda: To review and evaluate grant 

applications. 

Place: National Institutes of Health, Two 

Democracy Plaza, 6707 Democracy 

Boulevard, Bethesda, MD 20892 (Virtual 

Meeting). 

Contact Person: Karl F. Malik, Ph.D., 

Director Division of Extramural Activities, 

National Institutes of Diabetes and Digestive 

and Kidney Diseases, 6707 Democracy 

Boulevard, Room 7329, MSC 5452, Bethesda, 

MD 20892, (301) 594–4757, malikk@

niddk.nih.gov. 

Any interested person may file written 

comments with the committee by forwarding 

the statement to the Contact Person listed on 

this notice. The statement should include the 

name, address, telephone number and when 

applicable, the business or professional 

affiliation of the interested person. 

Information is also available on the 

Institute’s/Center’s home page: 

www.niddk.nih.gov/fund/divisions/DEA/ 

Council/coundesc.htm., where an agenda and 

any additional information for the meeting 

will be posted when available. 

(Catalogue of Federal Domestic Assistance 

Program Nos. 93.847, Diabetes, 

Endocrinology and Metabolic Research; 

93.848, Digestive Diseases and Nutrition 

Research; 93.849, Kidney Diseases, Urology 

and Hematology Research, National Institutes 

of Health, HHS) 

Dated: December 18, 2020. 

Miguelina Perez, 

Program Analyst, Office of Federal Advisory 

Committee Policy. 

[FR Doc. 2020–28524 Filed 12–23–20; 8:45 am] 

BILLING CODE 4140–01–P 

DEPARTMENT OF HEALTH AND 

HUMAN SERVICES 

National Institutes of Health 

Prospective Grant of an Exclusive 

Patent License: Use of A CD47 

Phosphorodiamidate Morpholino 

Oligomer for the Treatment, 

Prevention, and Diagnosis Of Cancer 

AGENCY: National Institutes of Health, 

HHS. 

ACTION: Notice. 

SUMMARY: The National Cancer Institute, 

an institute of the National Institutes of 

Health, Department of Health and 

Human Services, is contemplating the 

grant of an Exclusive Patent License to 

practice the inventions embodied in the 

Patents and Patent Applications listed 

in the Supplementary Information 

section of this notice to Morphiex 

Biotherapeutics (‘‘Morphiex’’) located in 

Boston, MA. 

DATES: Only written comments and/or 

applications for a license which are 

received by the National Cancer 

Institute’s Technology Transfer Center 

on or before January 12, 2021 will be 

considered. 

ADDRESSES: Requests for copies of the 

patent application, inquiries, and 

comments relating to the contemplated 

an Exclusive Patent License should be 

directed to: Jaime M. Greene, Senior 

Licensing and Patenting Manager at 

greenejaime@mail.nih.gov. 

SUPPLEMENTARY INFORMATION: 

Intellectual Property 

• U.S. Provisional Patent Application 

No. 60/850,132, filed October 6, 2006, 

now abandoned (HHS Ref. No. E–227– 

2006–0–US–01); 

• U.S. Provisional Patent Application 

No. 60/864,153, filed November 02, 

2006, now abandoned (HHS Ref. No. E– 

227–2006–1–US–01); 

• U.S. Provisional Patent Application 

No. 60/888,754, filed February 07, 2007, 

now 

• abandoned (HHS Ref. No. E–227– 

2006–2–US–01); 

• U.S. Provisional Patent Application 

No. 60/910,549, filed April 06, 2007, 

now abandoned (HHS Ref. No. E–227– 

2006–3–US–01); 

• U.S. Provisional Patent Application 

No. 60/956,375, filed August 16, 2007, 

now abandoned (HHS Ref. No. E–227– 

2006–4–US–01); 

• PCT Patent Application No. PCT/ 

2007/080647, filed October 5, 2007, now 

abandoned (HHS Ref. No. E–227–2006– 

5–PCT–01); 

• U.S. Patent No. 8,236,313, filed 

April 3, 2009, issued August 7, 2012 

(HHS Ref. No. E–227–2006–5–US–02); 

• Canadian Patent Application No. 

2,665,287, October 5, 2007 (HHS Ref. 

No. E–227–2006–5–CA–03); 

• Australian Patent No. 2007319576, 

filed October 5, 2007, issued May 1, 

2014 (HHS Ref. No. E–227–2006–5–AU– 

04); 

• European Patent No. 2076537, filed 

March 27, 2009, issued August 22, 2018 

(HHS Ref. No. E–227–2006–5–EP–05); 

• U.S. Patent Application No. 13/ 

546,931, filed July 11, 2012 (HHS Ref. 

No. E–227–2006–5–US–06); 

• U.S. Patent Number 8,557,788, filed 

July 11, 2012, issued October 15, 2013 

(HHS Ref. No. E–227–2006–5–US–07); 

• European Patent No. 2695896, filed 

October 5, 2007, issued August 22, 

2018(HHS Ref. No. E–227–2006–5–EP– 

08); 

• Australian Patent No. 2014201936, 

filed April 4, 2014, issued October 20, 

2016 (HHS Ref. No. E–227–2006–5–AU– 

09); 

• U.S. Patent No. 10370439, filed 

September 29, 2014, issued August 6, 

2019 (HHS Ref. No. E–227–2006–5–US– 

10); 

• Australian Patent No. 2016238894, 

filed October 6, 2016, issued February 

22, 2018 (HHS Ref. No. E–227–2006–5– 

AU–11); 

• Australian Patent No. 2018200921, 

filed February 8, 2018, issued 

September 24, 2020 (HHS Ref. No. E– 

227–2006–5–AU–12) 


tkelley on DSKBCP9HB2PROD with NOTICES